<DOC>
	<DOCNO>NCT01887457</DOCNO>
	<brief_summary>This trial determine whether give patient tailor dose voriconazole safe effective .</brief_summary>
	<brief_title>Individualisation Voriconazole Antifungal Therapy Antifungal Therapy</brief_title>
	<detailed_description>Invasive fungal infection major cause morbidity mortality patient haematological malignancy haematopoietic stem cell transplantation . Voriconazole routinely use first-line agent treatment invasive aspergillosis , invasive fusariosis scedosporiosis . Voriconazole extreme pharmacokinetic variability . Adult patient trough concentration &lt; 1 mg/L low probability clinical response whereas patient trough concentration &gt; 6 mg/L high probability toxicity . Therapeutic drug monitoring dose adjustment advocate algorithms enable voriconazole dosage reliably adjust achieve desire trough concentration timely optimally precise manner . Novel way deliver optimise antifungal therapy urgently require trial evaluate whether give patient tailor dose voriconazole safe effective . Plasma concentration take real time inputted dose software calculate optimum dose require trough concentration 1-3 mg/L . The software develop use data phase I III trial voriconazole .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Any adult ≥18 year old Patients new course voriconazole indicate suspect confirmed invasive aspergillosis serious fungal infection deem treat physician susceptible voriconazole Patients must venous access permit administration voriconazole enable procurement multiple plasma sample measure voriconazole concentration . Estimated creatinine clearance ≥ 50 mL/min Able give write informed consent Considered fit receive trial treatment Able remain hospital least 5 day complete trial treatment Female patient must satisfy investigator pregnant , childbearing potential , use adequate contraception Men must also use adequate contraception Patients estimate creatinine clearance &lt; 50 mL/minute ( precludes use intravenous voriconazole ) Patients receive form renal replacement therapy i.e . haemodialysis haemofiltration Patients hepatic insufficiency Female patient pregnant , breast feeding planning pregnancy study Past history intolerance voriconazole Age &lt; 18 Evidence clinically relevant fungal isolate resistant voriconazole QT prolongation ECG Use medication contraindicate use voriconazole Patients receive medication contraindicate use voriconazole i.e . terfenadine , long act barbiturate , ergot alkaloid , etc . ( Refer SMPC ) . Only patient rifampicin , rifabutin , phenytoin , carbamazepine would voriconazole preclude . Voriconazole influence pharmacokinetics many additional agent ( see SMPC ) importantly antirejection compound cyclosporine , tacrolimus ] Uncontrolled cardiac , respiratory disease serious medical psychiatric disorder would preclude trial therapy inform consent . Hypersensitivity Voriconazole , excipients triazoles</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>VFEND</keyword>
	<keyword>individualise</keyword>
	<keyword>personalise</keyword>
</DOC>